Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesObstetrics/GynecologyBCBSRI maternal serum biomarker Coverage Update | …
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

    View PDF of Maternal Serum Biomarkers for Prediction of Adverse Obstetric Outcomes, Effective 10/1/2026 in Medical

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Blue Cross Blue Shield - Rhode Island's coverage stance for specific maternal serum biomarker tests (PlGF Preeclampsia Screen CPT 0243U; PreTRM CPT 0247U; PreClara sFlt-1/PlGF CPT 0524U) for prediction of preeclampsia and spontaneous preterm birth for Medicare Advantage and Commercial Products, including prior authorization and laboratory participation rules.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyView PDF of Maternal Serum Biomarkers for Prediction of Adverse Obstetric Outcomes, Effective 10/1/2026 in Medical
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 3, 2026
    Next Review Date
    Key ActionOnly the ordering physician may be involved in authorization, appeal, or other administrative processes related to prior authorization/medical necessity; labs and third parties must not obtain authorization on behalf of the ordering physician.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical/coverage changes.

    3Specific CPT codes listed as not covered / not medically necessary
    Medicare Advantage & CommercialPlans affected
    DRAFTPolicy status

    Coverage Summary

    This DRAFT policy defines Blue Cross Blue Shield – Rhode Island's coverage stance for specific maternal serum biomarker tests for prediction of preeclampsia and spontaneous preterm birth (including CPT 0243U, 0247U, and 0524U).

    Policy status: DRAFT. Effective date: 2026-10-01. Last review: 2026-06-03.

    Policy attributes
    PayerBlue Cross Blue Shield - Rhode Island
    Policy titleMaternal serum biomarker testing for prediction of preeclampsia and spontaneous preterm birth
    Plans affectedMedicare Advantage & Commercial
    Policy statusDRAFT
    Effective date2026-10-01
    Last review2026-06-03

    Medical-Necessity Criteria

    Coverage Determinations

    Coverage determinations for maternal serum biomarker tests:

    ALL of the following

    • For Medicare Advantage Plans: Maternal serum biomarker tests (including maternal serum cell-free RNA tests), with or without additional algorithmic analysis, for prediction of preeclampsia are considered not covered.

      Applies to listed CPT codes and similar tests

    • For Commercial Products: Maternal serum biomarker tests (including maternal serum cell-free RNA tests), with or without additional algorithmic analysis, for prediction of preeclampsia are considered not medically necessary.

      Applies to listed CPT codes and similar tests

    • For Medicare Advantage Plans: Maternal serum biomarker tests, with or without additional algorithmic analysis, for prediction of spontaneous preterm birth are considered not covered.

    Prior Authorization & Operational Rules

    Prior Authorization

    Operational prior authorization rules and laboratory participation constraints:

    ALL of the following

    • Prior authorization: Not applicable.

      Policy states 'Not applicable' for prior authorization generally

    • Only the ordering physician shall be involved in the authorization, appeal or other administrative processes related to prior authorization/medical necessity; laboratories and third parties are prohibited from obtaining authorization or participating on behalf of the ordering physician.

      Violations may result in termination from BCBSRI provider network and laboratory financial liability for unauthorized services

    Documentation Required

    Coding

    Not covered / Not medically necessary CPT codesCPTNot Covered
    0243UObstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia (PlGF Preeclampsia Screen)
    0247UObstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth (PreTRM)
    0524UObstetrics (preeclampsia), sFlt-1/PlGF ratio, immunoassay, utilizing serum or plasma, reported as a value (PreClara Ratio) (Test Name Revision Effective 1/1/2026)

    Background & Evidence Summary

    Maternal serum biomarker tests are proposed as adjuncts to standard screening to identify pregnant people at risk for preeclampsia and spontaneous preterm birth, with the goal of improving early identification and guiding interventions.

    Some sFlt-1/PlGF ratio assays (KRYPTOR and Elecsys) have FDA clearances for specific inpatient prognostic use among hospitalized women with hypertensive disorders of pregnancy (gestational age ~23+0 to 34+6/7 weeks) to aid risk assessment for progression to severe preeclampsia within 2 weeks of presentation.

    Overall, observational studies, systematic reviews, and randomized trials to date are considered insufficient to demonstrate improved net health outcomes for broader predictive or screening use across evaluated populations.

    Key evidence items
    PRAECIS cutoff proposedKRYPTOR >40; Elecsys <38 (cutoffs reported but variable across studies)
    Regulatory clearances notedKRYPTOR De Novo DEN220027 (May 2023); Elecsys cleared Feb 2025
    RCTs for PreTRM / biomarker-guided interventionsMixed results; PRIME RCT showed reduced neonatal morbidity but overall evidence insufficient

    Not Covered / Not Medically Necessary

    For Medicare Advantage Plans: maternal serum biomarker tests (including maternal serum cell-free RNA tests), with or without additional algorithmic analysis, for prediction of preeclampsia and for prediction of spontaneous preterm birth are considered not covered because the evidence is insufficient to show improved net health outcomes.

    For Commercial Products: these tests are considered not medically necessary for prediction of preeclampsia and spontaneous preterm birth for the same reason.

    Although some sFlt-1/PlGF ratio assays (KRYPTOR, Elecsys) have FDA clearance for specific inpatient prognostic use in hospitalized women with hypertensive disorders of pregnancy, broader outpatient screening or predictive use across populations lacks sufficient evidence and is not covered/not medically necessary.

    Definitions

    Preeclampsia: New onset maternal hypertension and proteinuria or new onset hypertension and significant end-organ dysfunction (with or without proteinuria) after 20 weeks' gestation.

    Preterm birth: Birth occurring between 20 and 37 weeks of pregnancy; spontaneous or iatrogenic.

    Revision History

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyView PDF of Maternal Serum Biomarkers for Prediction of Adverse Obstetric Outcomes, Effective 10/1/2026 in Medical
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 3, 2026
    Next Review Date
    Key ActionOnly the ordering physician may be involved in authorization, appeal, or other administrative processes related to prior authorization/medical necessity; labs and third parties must not obtain authorization on behalf of the ordering physician.
    SourceLink
    On This Page
    Coverage SummaryMedical-Necessity CriteriaPrior Authorization & Operational RulesCodingBackground & Evidence SummaryNot Covered / Not Medically NecessaryDefinitionsRevision History
    For Commercial Products: Maternal serum biomarker tests, with or without additional algorithmic analysis, for prediction of spontaneous preterm birth are considered not medically necessary.
  1. Benefits may vary by group/contract; refer to Evidence of Coverage or Subscriber Agreement for specific not medically necessary / not covered laboratory benefits.

    Some self-funded groups may have contract exclusions per the Biomarker Testing Mandate policy

  2. Ordering physician must handle authorization/appeals

    Only the ordering physician may be involved in authorization, appeal, or other administrative processes related to prior authorization/medical necessity; labs and third parties must not obtain authorization on behalf of the ordering physician.

    Denial Risk

    Unauthorized laboratory services will be denied and financially liable

    If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.

    Preeclampsia: New onset maternal hypertension and proteinuria or new onset hypertension and significant end-organ dysfunction (with or without proteinuria) after 20 weeks' gestation.

    Preterm birth: Birth occurring between 20 and 37 weeks of pregnancy; spontaneous or iatrogenic.